Biosimilar Antibodies

Sirtratumab is a human IgG2 monoclonal antibody specifically targeting SLIT and NTRK-like family 6 (Slitrk6). This antibody is designed for use in cancer research, facilitating the investigation of Slitrk6's role and mechanisms in oncogenesis. Sirtratumab's high specificity makes it a valuable tool for detailed studies focusing on the molecular pathways influenced by Slitrk6 in various cancer models.

Ianalumab (VAY-736) is a humanized, decarboxylated monoclonal antibody that specifically targets BAFF-R (B-cell activating factor receptor). This antibody effectively blocks the interaction between BAFF (B-cell activating factor) and its receptor BAFF-R, thereby inhibiting the BAFF-mediated protection from apoptosis. Additionally, Ianalumab promotes antibody-dependent cellular cytotoxicity (ADCC) through the activation of effector cells mediated by the immune receptor tyrosine-based activation motif (ITAM). This dual mechanism of action makes Ianalumab a valuable tool for research into B-cell regulation and autoimmune disease therapies.

Bafisontamab (EMB-01) is a bispecific monoclonal antibody designed for targeted cancer therapy. It simultaneously binds to the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (c-MET), exhibiting potent antitumor activity. This dual targeting mechanism disrupts critical pathways involved in tumor growth and survival, making Bafisontamab a valuable tool for research in oncology.

Galvokimig is a monoclonal antibody designed to target and neutralize interleukin 13 (IL-13), interleukin 17A (IL-17A), albumin (ALB), and interleukin 17B (IL-17B). This antibody is engineered for high specificity and affinity, making it suitable for use in research studies investigating the roles and interactions of these cytokines in various inflammatory and autoimmune conditions. Galvokimig can be applied in a range of experimental setups, including immunoassays, functional studies, and as a potential therapeutic strategy model.

Gorivitug is a human IgG1 κ monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

The Anti-MUC16 Antibody (VK8) is a chimeric mouse monoclonal antibody of the IgG1 kappa subclass, designed to specifically target human MUC16. For accurate experimental control, it is recommended to use Mouse IgG1 kappa, Isotype Control as the appropriate isotype control for this antibody.

Greziprubart is a human monoclonal antibody of the IgG1κ isotype designed to specifically target C5a. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Acasunlimab (GEN1046) is a bispecific antibody designed to simultaneously target PD-L1 and 4-1BB. This innovative therapeutic agent facilitates the enhancement of T-cell and NK-cell activity via conditional stimulation of 4-1BB, while consistently inhibiting the PD-1/PD-L1 axis. Acasunlimab is primarily utilized in cancer research, focusing on its potential to modulate immune checkpoint pathways and improve antitumor responses.

Isecarosmab (M-6495) is a monoclonal antibody targeting ADAMTS with a dissociation constant (K_D) of 3.65 pM, indicative of high affinity binding. This antibody exhibits chondroprotective and anti-inflammatory properties, making it valuable in research focused on inflammatory and degenerative joint diseases. Additionally, Isecarosmab has been engineered to bind albumin, which enhances its plasma half-life, thereby potentially improving its therapeutic efficacy and stability in physiological conditions.

Manelimab is a monoclonal antibody designed to selectively inhibit programmed death-ligand 1 (PD-L1), a key molecular target involved in the suppression of the immune response, particularly in the context of tumor evasion. This antibody has potential applications in oncological research and therapeutic interventions aimed at enhancing immune system activity against various cancers.

Cafelkibart is a chimeric IgG1κ monoclonal antibody specifically designed to target CCR8. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Lutikizumab (ABT-981) is a dual variable domain immunoglobulin designed to specifically target and inhibit both interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). This monoclonal antibody functions by binding to these cytokines, effectively neutralizing their activity and mitigating their pro-inflammatory effects. Lutikizumab is primarily utilized in research focused on understanding and treating osteoarthritis, providing a valuable tool for investigating the role of IL-1 in inflammatory processes associated with this degenerative disease.

Infliximab, marketed under the name Avakine, is a chimeric monoclonal IgG1 antibody that selectively targets and binds to tumor necrosis factor alpha (TNF-α). By inhibiting the interaction between TNF-α and its receptors (TNFR1 and TNFR2), Infliximab effectively modulates inflammatory responses. This antibody is widely utilized in research focused on autoimmune diseases, chronic inflammatory conditions, and diabetic neuropathy, offering significant potential for elucidating disease mechanisms and therapeutic interventions.

Galegenimab, designated as FHTR 2163, RG 6147, and RO 7171009, is a monoclonal antibody fragment targeting High-temperature requirement A serine peptidase 1 (HTRA1). This antibody fragment is specifically developed for the investigation of its therapeutic potential in age-related macular degeneration (AMD). Galegenimab is utilized primarily in research settings to explore the pathological mechanisms of AMD and to assess its efficacy as a potential treatment modality.

Carlumab (CNTO 888) is a human monoclonal antibody that exhibits high affinity for chemokine ligand 2 (CCL2). This antibody is particularly utilized in the study of cancer mechanisms, with a focus on prostate cancer research. Carlumab's ability to target CCL2 makes it a valuable tool for investigating the role of this chemokine in tumor microenvironments and its potential impact on cancer progression and metastasis.

Lancastotug is a human IgG1 κ monoclonal antibody targeting TIGIT. For optimal experimental control, the use of Human IgG1 kappa Isotype Control is recommended.

Fulranumab is a human IgG2 monoclonal antibody that targets nerve growth factor (NGF), making it a valuable tool for pain research. This antibody binds specifically to NGF, a key mediator in the development and sensation of pain, potentially inhibiting its biological activity and providing insights into pain management mechanisms. Fulranumab is suitable for various experimental applications to explore the role of NGF in pain pathways and therapeutic interventions.

Anrukinzumab (IMA-638) is a humanized monoclonal antibody that targets interleukin-13 (IL-13), a cytokine implicated in the pathogenesis of several inflammatory conditions. This antibody has demonstrated efficacy in reducing lung inflammation in cynomolgus monkey models, highlighting its potential utility in pulmonary research. Anrukinzumab is suitable for use in investigations into the mechanisms and treatment of diseases such as ulcerative colitis and asthma, providing a valuable tool for both basic research and therapeutic development.

Lokivetmab is a recombinant monoclonal antibody specifically targeting canine interleukin-31 (IL-31). This antibody is utilized primarily in the study of atopic dermatitis in dogs, providing a valuable tool for understanding the pathophysiology of this condition and the role of IL-31 in canine allergic responses.

R707 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets CCR7/CD197, a chemokine receptor involved in the regulation of leukocyte migration. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.36 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Etrolizumab, also known as rhuMAb Beta7, is a gut-selective monoclonal antibody that selectively targets the β7 subunit of α4β7 and αEβ7 integrins. This antibody demonstrates high affinity binding, with dissociation constants (Ki) of 18 nM for Human α4β7 and 1.8 nM for Human αEβ7-293 integrins. Etrolizumab is primarily utilized in the research of inflammatory bowel diseases (IBD), making it a valuable tool for studies aimed at understanding and potentially treating these conditions.

ABT-325 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting interleukin-18 (IL-18). This antibody is composed of a human IgG1 type heavy chain and a human kappa (huκ) type light chain. ABT-325 has a predicted molecular weight of 146.28 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is suitable for a range of immunological applications where IL-18 activity modulation is investigated.

Plonmarlimab (TJ003234) is a monoclonal antibody targeting Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). This antibody is utilized in the investigation of inflammatory conditions such as rheumatoid arthritis, as well as in the study of immune response mechanisms in COVID-19. Plonmarlimab offers a specific tool for researchers exploring the role of GM-CSF in disease pathology and therapeutic intervention.

The Anti-SCN9a/Nav1.7 Antibody is a human monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically targeting the SCN9a/Nav1.7 ion channel. This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This antibody is suitable for use in various biochemical and cellular research applications to study the role of the Nav1.7 channel in pain perception and other neurological functions.

Vonlerolizumab (MOXR 0916) is a humanized IgG monoclonal antibody that functions as an agonist targeting the OX40 receptor. This antibody is specifically designed for the study of cancer immunotherapy, facilitating research into the modulation of T-cell activity and the enhancement of anti-tumor immune responses.

Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody designed to selectively target and inhibit the complement C5a receptor 1 (C5aR1). By blocking the interaction between C5aR1 and its ligand C5a, Avdoralimab effectively prevents receptor activation, offering a therapeutic strategy for the study of complement-driven inflammatory diseases and solid tumors. This antibody is pivotal for researchers focusing on the role of the complement system in pathology and the therapeutic potential of complement inhibition.

Plozalizumab (MLN-1202) is a humanized monoclonal antibody that selectively targets the CCR2 (C-C chemokine receptor type 2) receptor. This specificity makes it a valuable tool for investigating the role of CCR2 in malignant melanoma, providing insights that may contribute to the development of targeted therapies for this aggressive cancer.

Tazlestobart is a humanized IgG1κ monoclonal antibody designed to specifically target CTLA4. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Lenzilumab (KB 003) is a humanized monoclonal antibody specifically designed to neutralize colony-stimulating factor 2 (CSF2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody is utilized in research focused on COVID-19 and myelomonocytic leukemias, including chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Its targeted action against CSF2/GM-CSF makes it a valuable tool for understanding and potentially modulating inflammatory and immune responses in these disease states.

Rilogrotug is a human monoclonal antibody of the IgG1κ subtype that specifically targets GDF15 (Growth Differentiation Factor 15). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

AMG-119 is a humanized IgG1 monoclonal antibody specifically designed to target delta-like ligand 3 (DLL3). This antibody is particularly useful in research focused on relapsed or refractory small cell lung cancer (SCLC). For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ monoclonal antibody designed to target human cytomegalovirus (hCMV). This antibody exhibits its neutralizing activity by specifically binding to antigenic domain 1 of glycoprotein B, which is located on the envelope of hCMV. Through this targeted interaction, Fiztasovimab effectively inhibits the cell-to-cell transmission of the virus, providing a crucial tool for research into viral pathogenesis and therapeutic intervention strategies.

Verzistobart is a monoclonal antibody of the IgG1κ class, specifically designed to bind to the hepatitis A virus cellular receptor, HAVCR2. This targeted interaction is crucial for research focused on the pathogenesis and therapeutic interventions of hepatitis A, providing a valuable tool for both in vitro and in vivo studies.

Rocatinlimab (AMG 451, KHK4083) is a fully human, non-fucosylated IgG1 monoclonal antibody targeting OX40. This antibody is designed for the investigation of therapeutic pathways in atopic dermatitis (AD) and may be utilized in related immunological research studies.

The Anti-STOP1 Antibody is a human monoclonal antibody derived from Chinese Hamster Ovary (CHO) cells, specifically targeting the STOP1 protein. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the function and regulation of the STOP1 protein.

Vibostolimab is a monoclonal antibody targeting TIGIT (T cell immunoglobulin and ITIM domain), demonstrating significant antitumor activity. This antibody is specifically designed for research involving non-small cell lung cancer (NSCLC) and melanoma, providing a valuable tool for investigations into immune checkpoint pathways and cancer immunotherapy.

Pivekimab is a human IgG1 monoclonal antibody engineered to specifically target interleukin-3 (IL-3) and CD123. This antibody serves as the foundational component in the synthesis of Pivekimab Sunirine, a targeted CD123-directed antibody-drug conjugate (ADC) utilized in therapeutic applications. Pivekimab is primarily employed in research focused on blastic plasmacytoid dendritic cell neoplasm (BPDCN), providing a critical tool for advancing studies in this area of oncology.

Canrivitug is a human IgG1 λ2 monoclonal antibody specifically targeting the SARS-CoV-2 virus. For accurate experimental control, it is recommended to use Human IgG1 lambda2 as an isotype control.

Gevokizumab is a potent monoclonal antibody that targets interleukin-1 beta (IL-1β), employing an allosteric mechanism to modulate IL-1β signaling negatively. This antibody selectively reduces the binding affinity of IL-1β to its signaling receptor, interleukin-1 receptor type I (IL-1RI), rather than affecting the interaction with the IL-1 counter-regulatory decoy receptor, interleukin-1 receptor type II (IL-1RII). This specificity in modulation facilitates the detailed study of IL-1β signaling pathways and their physiological and pathological roles. Gevokizumab is instrumental in research focused on inflammation and immune response, offering potential therapeutic insights into diseases mediated by IL-1β.

ICT-01 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting BTN1A1. This antibody is composed of an IgG1 type heavy chain and a human kappa (huκ) type light chain, with a predicted molecular weight of 146.2 kDa. For experimental controls, the recommended isotype control is Human IgG1 kappa.

Tilrekimig is a monoclonal antibody engineered to specifically target human interleukin 4 (IL-4), interleukin 13 (IL-13), and thymic stromal lymphopoietin (TSLP). This antibody is of significant interest for the study of allergic and inflammatory disorders, including asthma and atopic dermatitis. Its specificity for these cytokines makes it a valuable tool in the investigation of the underlying mechanisms of these diseases and the development of targeted therapies.

Coltuximab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CD19. This biologic is constructed from human immunoglobulin G1 (huIgG1) heavy chains and human kappa (huκ) light chains, exhibiting a predicted molecular weight of 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Cusatuzumab (ARGX-110) is a humanized monoclonal antibody targeting CD70. It exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) and effectively blocks the CD70/CD27 signaling pathway. By inhibiting this pathway, cusatuzumab reduces the population of leukemia stem cells (LSCs) and induces gene signatures associated with myeloid differentiation and apoptosis. This antibody is particularly useful in research focused on the pathophysiology and potential therapeutic interventions for leukemia.

Vixarelimab (KPL-716) is a human monoclonal antibody targeting the beta chain of the oncostatin M (OSM) receptor. By binding to this subunit, Vixarelimab effectively inhibits signaling pathways mediated by interleukin-31 (IL-31) and OSM. This antibody is particularly useful in research focused on inflammatory skin conditions, including atopic dermatitis and prurigo nodularis, providing a valuable tool for investigating the molecular mechanisms underlying these diseases and potentially guiding therapeutic interventions.

Lintuzumab (HUM-195) is a humanized monoclonal antibody targeting CD33, designed to modulate immune responses in acute myeloid leukemia (AML). By reducing the production of TNFα-induced pro-inflammatory cytokines and chemokines, Lintuzumab effectively suppresses inflammatory pathways in AML cells. It facilitates tumor cell eradication via mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), demonstrating efficacy against both multidrug-resistant (MDR) and non-resistant AML cell lines, as well as primary samples from AML patients. In vivo studies have shown that Lintuzumab significantly enhances survival rates and diminishes tumor burden in murine models, highlighting its potential as a therapeutic agent in oncology research.